{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"gray-platelet","columns":[{"gene":"","key":"population-96e38bcc08e36748bcfa","label":"Gray platelet syndrome","mondoId":"MONDO:0007686","onsetQualifier":null,"originColumnKey":"MONDO:0007686/OMIM:139090","originalViews":[{"key":"MONDO:0007686/OMIM:139090","label":"Gray platelet syndrome","scopeLabel":"OMIM:139090","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["55d63b99ae349af5632bb523533de98d4ff46cda4268ba719609a572dd007c44","6a5636657074f0fbfe1a0a9ab612854c2294775faf93d6d126e7448f9c21927b","6bf1176e3942812e29cb92a455e993f038d30a6480d5acfb6a1a5769ead36160","7c8744328b9017ad789438ca620424639223657991223cd0fc97d33c7647e2b5","8554ffea41b79a1a3b74d354da3592fbce6a97802bc12d81346d17619c1ca5ec","8ed6aec82367cfc93f86b883f26df84c11ab70b9257291a1d6ededb7a9da39ab","8f2ce66ef3ff9b0e551bdc1c6d3fe9c03b46abeb215b9fa90b1782cf3a65d330","c65a95f87377d8f08b5ee2f4ba914994c27ac94b6fac30f32d88ec120c26d388","d6ac613e954cc199e8834394c865d53a56807caa7965bcb4485d83e2d82860d4","d6b6293aeeef6d6771241e9942f5251ba6d73bc5a05bba8207e77aa2dd497bee","e4d60fea27de8b6f71ace7e58d044cc5092a2c2d68e300b14828c76e46814bb9","e93f941f8cfd2e301a7bb9f58726d235a5ce1f1993f30c759a7e75a50519825e","f2d3f478ac43534aba381d52fb0a62fbecca838a6198006accd2bb43ca3348f2"],"recordQualifiers":{},"scopeLabel":"OMIM:139090","sourceIds":["OMIM:139090"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."},{"gene":"","key":"population-fdee0847862e50536e0d","label":"Gray platelet syndrome","mondoId":"MONDO:0007686","onsetQualifier":null,"originColumnKey":"MONDO:0007686/ORPHA:721","originalViews":[{"key":"MONDO:0007686/ORPHA:721","label":"Gray platelet syndrome","scopeLabel":"ORPHA:721","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["1c09846bb88008553deab866684d2ce79048804f2427f957abc72e60fa0dc3cf","2fcd801ec9c9b87d7d516f7c3cf3a8b1f8ac20015356d06db8016eee661e13cf","8f5d76a1fefabb10e9d32094e959febb9fae56ec8a8740f2376c1b924a0df1c8","9ef8233d007d8cbed89f7b93caa38ac4ed713c9bff31b9a12010ea8617b9bd97","d251405d1a737b13198737ae954ce5305ef5c9ef1e6e707cc6f01a3a8720b41f","d4fa8b9d19eb1bce8d7d0e9a004ebb4b78ec3ee862a522388eecd8e2c3a93aab","d54a6bba008bf147ff1e6ac8f02b9e8a502b89a08115039fab1f7cc91b322898","d7c8cdf87a528661d1f9d2f2ab0f78d7215bf93852e9d625c94de443835a5cb1"],"recordQualifiers":{},"scopeLabel":"ORPHA:721","sourceIds":["ORPHA:721"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-96e38bcc08e36748bcfa","population-fdee0847862e50536e0d"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0001892","HP:0012528","HP:0000140","HP:0001872","HP:0000978","HP:0000421","HP:0008320"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":21,"sourceGroups":{"omim":12,"orphanet":8,"published":1}},"features":[{"hpoId":"HP:0001892","label":"Abnormal bleeding","primary":true},{"hpoId":"HP:0012528","label":"Abnormal number of alpha granules","primary":true},{"hpoId":"HP:0000140","label":"Abnormality of the menstrual cycle","primary":true},{"hpoId":"HP:0001872","label":"Abnormality of thrombocytes","primary":true},{"hpoId":"HP:0000978","label":"Bruising susceptibility","primary":true},{"hpoId":"HP:0000421","label":"Epistaxis","primary":true},{"hpoId":"HP:0008320","label":"Impaired collagen-induced platelet aggregation","primary":true},{"hpoId":"HP:0011872","label":"Impaired thrombin-induced platelet aggregation","primary":false},{"hpoId":"HP:0000132","label":"Menorrhagia","primary":false},{"hpoId":"HP:0002863","label":"Myelodysplasia","primary":false},{"hpoId":"HP:0011974","label":"Myelofibrosis","primary":false},{"hpoId":"HP:0003010","label":"Prolonged bleeding time","primary":false},{"hpoId":"HP:0012147","label":"Reduced quantity of Von Willebrand factor","primary":false},{"hpoId":"HP:0008330","label":"Reduced von Willebrand factor activity","primary":false},{"hpoId":"HP:0001744","label":"Splenomegaly","primary":false},{"hpoId":"HP:0001873","label":"Thrombocytopenia","primary":false}],"ledeHtml":"Gray platelet syndrome is a bleeding disorder associated with abnormal platelets, which are small blood cells involved in blood clotting. People with this condition tend to bruise easily and have an increased risk of nosebleeds (epistaxis). They may also experience abnormally heavy or extended bleeding following surgery, dental work, or minor trauma. Women with gray platelet syndrome often have irregular, heavy periods (menometrorrhagia). These bleeding problems are usually mild to moderate, but they have been life-threatening in a few affected individuals.","mondoId":"MONDO:0007686","node":{"canonicalSlug":"gray-platelet","comparisons":[{"documentSha256":"370fc9279cb642e401f9b5542a2fa25878dd2713db9ca4f0825034059073ddd3","key":"legacy-gray-platelet","kind":"legacy","label":"gray platelet syndrome","memberIds":["MONDO:0007686"],"mondoId":"MONDO:0007686","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/gray-platelet.370fc9279cb642e401f9b5542a2fa25878dd2713db9ca4f0825034059073ddd3.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":["Gray platelet syndrome can be caused by mutations in the NBEAL2 gene. Little is known about the protein produced from this gene. It appears to play a role in the formation of alpha-granules, which are sacs inside platelets that contain growth factors and other proteins that are important for blood clotting and wound healing. In response to an injury that causes bleeding, the proteins stored in alpha-granules help platelets stick to one another to form a plug that seals off damaged blood vessels and prevents further blood loss.","Mutations in the NBEAL2 gene disrupt the normal production of alpha-granules. Without alpha-granules, platelets are unusually large and fewer in number than usual (macrothrombocytopenia). The abnormal platelets also appear gray when viewed under a microscope, which gives this condition its name. A lack of alpha-granules impairs the normal activity of platelets during blood clotting, increasing the risk of abnormal bleeding. Myelofibrosis is thought to occur because the growth factors and other proteins that are normally packaged into alpha-granules leak out into the bone marrow. The proteins lead to fibrosis that affects the bone marrow's ability to make new blood cells.","Some people with gray platelet syndrome do not have an identified mutation in the NBEAL2 gene. In these individuals, the cause of the condition is unknown."],"causesUrl":"https://medlineplus.gov/genetics/condition/gray-platelet-syndrome/#causes","contentForm":"summary","matchMethod":"automatic-preferred-name","name":"Gray platelet syndrome","paragraphs":["Gray platelet syndrome is a bleeding disorder associated with abnormal platelets, which are small blood cells involved in blood clotting. People with this condition tend to bruise easily and have an increased risk of nosebleeds (epistaxis). They may also experience abnormally heavy or extended bleeding following surgery, dental work, or minor trauma. Women with gray platelet syndrome often have irregular, heavy periods (menometrorrhagia). These bleeding problems are usually mild to moderate, but they have been life-threatening in a few affected individuals.","A condition called myelofibrosis, which is a buildup of scar tissue (fibrosis) in the bone marrow, is another common feature of gray platelet syndrome. Bone marrow is the spongy tissue in the center of long bones that produces most of the blood cells the body needs, including platelets. The scarring associated with myelofibrosis damages bone marrow, preventing it from making enough blood cells. Other organs, particularly the spleen, start producing more blood cells to compensate; this process often leads to an enlarged spleen (splenomegaly)."],"reviewed":"2014-09","scope":"exact","scopeNote":"","source":"MedlinePlus","sourceRelease":"2026-10-01","upstream":"MedlinePlus Genetics","url":"https://medlineplus.gov/genetics/condition/gray-platelet-syndrome"},"ownColumnKeys":["population-96e38bcc08e36748bcfa","population-fdee0847862e50536e0d"],"publication":"published","relationships":[{"kind":"parent","label":"inherited bleeding disorder, platelet-type","mondoId":"MONDO:0000009","slug":null},{"kind":"parent","label":"syndromic disease","mondoId":"MONDO:0002254","slug":null},{"kind":"parent","label":"alpha granule disease","mondoId":"MONDO:0020117","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending","articles":[{"articleId":"rarediseases.info.nih.gov/diseases/2562","pageMondoId":"MONDO:0007686","source":"GARD","name":"Gray platelet syndrome","url":"https://rarediseases.info.nih.gov/diseases/2562","relationToPage":"same-condition","coveredMondoIds":["MONDO:0007686"],"status":"validated-exact-source","presentation":"additional-reference","evidence":["existing-offline-scope-validator","automatic-identity-and-attribution"],"reviewed":null,"sourceRelease":"2026-10-21T17:04:05Z","upstream":"GARD:0002562","rawAttribution":"MONDO:0007686","independentCorroborationEstablished":false}]},"records":[{"frequencyKind":"range","key":"1c09846bb88008553deab866684d2ce79048804f2427f957abc72e60fa0dc3cf","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:721","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001872","is_excluded":false,"label":"Abnormality of thrombocytes","onset_id":null,"reference":"ORPHA:721","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2fcd801ec9c9b87d7d516f7c3cf3a8b1f8ac20015356d06db8016eee661e13cf","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:721","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001892","is_excluded":false,"label":"Abnormal bleeding","onset_id":null,"reference":"ORPHA:721","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"55d63b99ae349af5632bb523533de98d4ff46cda4268ba719609a572dd007c44","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0012147","is_excluded":false,"label":"Reduced quantity of Von Willebrand factor","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"6a5636657074f0fbfe1a0a9ab612854c2294775faf93d6d126e7448f9c21927b","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000421","is_excluded":false,"label":"Epistaxis","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"6bf1176e3942812e29cb92a455e993f038d30a6480d5acfb6a1a5769ead36160","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001873","is_excluded":false,"label":"Thrombocytopenia","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"7c8744328b9017ad789438ca620424639223657991223cd0fc97d33c7647e2b5","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003010","is_excluded":false,"label":"Prolonged bleeding time","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"8554ffea41b79a1a3b74d354da3592fbce6a97802bc12d81346d17619c1ca5ec","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0011872","is_excluded":false,"label":"Impaired thrombin-induced platelet aggregation","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"8ed6aec82367cfc93f86b883f26df84c11ab70b9257291a1d6ededb7a9da39ab","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0011974","is_excluded":false,"label":"Myelofibrosis","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"8f2ce66ef3ff9b0e551bdc1c6d3fe9c03b46abeb215b9fa90b1782cf3a65d330","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0008320","is_excluded":false,"label":"Impaired collagen-induced platelet aggregation","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"8f5d76a1fefabb10e9d32094e959febb9fae56ec8a8740f2376c1b924a0df1c8","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:721","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000978","is_excluded":false,"label":"Bruising susceptibility","onset_id":null,"reference":"ORPHA:721","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"9ef8233d007d8cbed89f7b93caa38ac4ed713c9bff31b9a12010ea8617b9bd97","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:721","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001873","is_excluded":false,"label":"Thrombocytopenia","onset_id":null,"reference":"ORPHA:721","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"c65a95f87377d8f08b5ee2f4ba914994c27ac94b6fac30f32d88ec120c26d388","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0008330","is_excluded":false,"label":"Reduced von Willebrand factor activity","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"d251405d1a737b13198737ae954ce5305ef5c9ef1e6e707cc6f01a3a8720b41f","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:721","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001744","is_excluded":false,"label":"Splenomegaly","onset_id":null,"reference":"ORPHA:721","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d4fa8b9d19eb1bce8d7d0e9a004ebb4b78ec3ee862a522388eecd8e2c3a93aab","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:721","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002863","is_excluded":false,"label":"Myelodysplasia","onset_id":null,"reference":"ORPHA:721","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d54a6bba008bf147ff1e6ac8f02b9e8a502b89a08115039fab1f7cc91b322898","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:721","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000421","is_excluded":false,"label":"Epistaxis","onset_id":null,"reference":"ORPHA:721","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"d6ac613e954cc199e8834394c865d53a56807caa7965bcb4485d83e2d82860d4","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000132","is_excluded":false,"label":"Menorrhagia","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"d6b6293aeeef6d6771241e9942f5251ba6d73bc5a05bba8207e77aa2dd497bee","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000978","is_excluded":false,"label":"Bruising susceptibility","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"d7c8cdf87a528661d1f9d2f2ab0f78d7215bf93852e9d625c94de443835a5cb1","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:721","disease_name":"Gray platelet syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000140","is_excluded":false,"label":"Abnormality of the menstrual cycle","onset_id":null,"reference":"ORPHA:721","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"e4d60fea27de8b6f71ace7e58d044cc5092a2c2d68e300b14828c76e46814bb9","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0012528","is_excluded":false,"label":"Abnormal number of alpha granules","onset_id":null,"reference":"PMID:21765412","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"e93f941f8cfd2e301a7bb9f58726d235a5ce1f1993f30c759a7e75a50519825e","raw":{"aspect":"P","body_system":"digestive","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001744","is_excluded":false,"label":"Splenomegaly","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"f2d3f478ac43534aba381d52fb0a62fbecca838a6198006accd2bb43ca3348f2","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:139090","disease_name":"Gray platelet syndrome","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001892","is_excluded":false,"label":"Abnormal bleeding","onset_id":null,"reference":"OMIM:139090","source_release":"2026-06-23"},"sourceGroups":["omim"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/gray-platelet-syndrome\" rel=\"noreferrer\">MedlinePlus</a></p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/2562\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0007686\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-preferred-name</dd><dt>Upstream attribution</dt><dd>MedlinePlus Genetics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Gray platelet syndrome is a bleeding disorder associated with abnormal platelets, which are small blood cells involved in blood clotting. People with this condition tend to bruise easily and have an increased risk of nosebleeds (epistaxis). They may also experience abnormally heavy or extended bleeding following surgery, dental work, or minor trauma. Women with gray platelet syndrome often have irregular, heavy periods (menometrorrhagia). These bleeding problems are usually mild to moderate, but they have been life-threatening in a few affected individuals.</p><p>A condition called myelofibrosis, which is a buildup of scar tissue (fibrosis) in the bone marrow, is another common feature of gray platelet syndrome. Bone marrow is the spongy tissue in the center of long bones that produces most of the blood cells the body needs, including platelets. The scarring associated with myelofibrosis damages bone marrow, preventing it from making enough blood cells. Other organs, particularly the spleen, start producing more blood cells to compensate; this process often leads to an enlarged spleen (splenomegaly).</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/gray-platelet-syndrome\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"overview","title":"Overview"},{"bodyHtml":"<p>Gray platelet syndrome can be caused by mutations in the NBEAL2 gene. Little is known about the protein produced from this gene. It appears to play a role in the formation of alpha-granules, which are sacs inside platelets that contain growth factors and other proteins that are important for blood clotting and wound healing. In response to an injury that causes bleeding, the proteins stored in alpha-granules help platelets stick to one another to form a plug that seals off damaged blood vessels and prevents further blood loss.</p><p>Mutations in the NBEAL2 gene disrupt the normal production of alpha-granules. Without alpha-granules, platelets are unusually large and fewer in number than usual (macrothrombocytopenia). The abnormal platelets also appear gray when viewed under a microscope, which gives this condition its name. A lack of alpha-granules impairs the normal activity of platelets during blood clotting, increasing the risk of abnormal bleeding. Myelofibrosis is thought to occur because the growth factors and other proteins that are normally packaged into alpha-granules leak out into the bone marrow. The proteins lead to fibrosis that affects the bone marrow&#x27;s ability to make new blood cells.</p><p>Some people with gray platelet syndrome do not have an identified mutation in the NBEAL2 gene. In these individuals, the cause of the condition is unknown.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/gray-platelet-syndrome/#causes\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"causes","title":"Causes"}],"sharedSources":[],"slug":"gray-platelet","sourceDocuments":[{"name":"MedlinePlus: Gray platelet syndrome","reviewed":"2014-09","source_release":"2026-10-01","url":"https://medlineplus.gov/genetics/condition/gray-platelet-syndrome"},{"name":"GARD: Gray platelet syndrome","reviewed":null,"source_release":"2026-10-21T17:04:05Z","url":"https://rarediseases.info.nih.gov/diseases/2562"},{"name":"MONDO: gray platelet syndrome","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0007686"}],"sourceNote":"","synonyms":["Alpha storage pool deficiency","BDPLT4","GPS","gray platelet syndrome","marked decrease or absence of alpha-granules and of platelet-specific alpha-granule proteins","platelet alpha-granule deficiency"],"takeawayHtml":"","title":"gray platelet syndrome"},"schemaVersion":1}
